ES2054029T3 - Formulacion de acetato de flecainida con liberacion controlada. - Google Patents

Formulacion de acetato de flecainida con liberacion controlada.

Info

Publication number
ES2054029T3
ES2054029T3 ES89312107T ES89312107T ES2054029T3 ES 2054029 T3 ES2054029 T3 ES 2054029T3 ES 89312107 T ES89312107 T ES 89312107T ES 89312107 T ES89312107 T ES 89312107T ES 2054029 T3 ES2054029 T3 ES 2054029T3
Authority
ES
Spain
Prior art keywords
controlled release
flecainide acetate
acetate formulation
formulation
flecainide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89312107T
Other languages
English (en)
Inventor
David Porter
Andrew M Twitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riker Laboratories Inc
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Application granted granted Critical
Publication of ES2054029T3 publication Critical patent/ES2054029T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

SE PRESENTAN FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA QUE CONTIENEN ACETATO DE FLECAINURO Y METODOS PARA SUPRIMIR LA ARRITMIA USANDO LAS FORMULACIONES DESCRITAS.
ES89312107T 1988-11-30 1989-11-22 Formulacion de acetato de flecainida con liberacion controlada. Expired - Lifetime ES2054029T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/277,899 US4938966A (en) 1988-11-30 1988-11-30 Controlled release flecainide acetate formulation

Publications (1)

Publication Number Publication Date
ES2054029T3 true ES2054029T3 (es) 1994-08-01

Family

ID=23062855

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89312107T Expired - Lifetime ES2054029T3 (es) 1988-11-30 1989-11-22 Formulacion de acetato de flecainida con liberacion controlada.

Country Status (10)

Country Link
US (1) US4938966A (es)
EP (1) EP0371683B1 (es)
JP (1) JP3004663B2 (es)
AU (1) AU619917B2 (es)
CA (1) CA2002337C (es)
CS (1) CS390791A3 (es)
DE (1) DE68906132T2 (es)
ES (1) ES2054029T3 (es)
HK (1) HK1004887A1 (es)
NZ (1) NZ231308A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EP2359814A1 (en) 2010-02-11 2011-08-24 Laboratorios Liconsa, S.A. Pharmaceutical mini-tablets for sustained release of flecainide acetate
US20150164871A1 (en) * 2012-06-13 2015-06-18 Acesion Pharma Pharmaceutical Compositions for Combination Therapy
WO2020236631A1 (en) * 2019-05-17 2020-11-26 Alsar Ltd Partnership Flecainide combination and controlled-release formulations for treating heart diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005209A (en) * 1974-04-01 1977-01-25 Riker Laboratories, Inc. Antiarrhythmic method utilizing fluoroalkoxy-N-piperidyl and pyridyl benzamides
US3900481A (en) * 1974-04-01 1975-08-19 Riker Laboratories Inc Derivatives of pyrrolidine and piperidine
US3987201A (en) * 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4285955A (en) * 1978-10-31 1981-08-25 Bayer Aktiengesellschaft 1,4-Dihydropyridinecarboxylic acids
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JPS63267720A (ja) * 1987-04-24 1988-11-04 Morishita Seiyaku Kk エモルフアゾンの徐放性製剤

Also Published As

Publication number Publication date
US4938966A (en) 1990-07-03
NZ231308A (en) 1991-10-25
CS390791A3 (en) 1992-06-17
CA2002337A1 (en) 1990-05-31
DE68906132T2 (de) 1993-10-14
AU619917B2 (en) 1992-02-06
HK1004887A1 (en) 1998-12-11
JPH02193923A (ja) 1990-07-31
DE68906132D1 (de) 1993-05-27
EP0371683B1 (en) 1993-04-21
AU4551589A (en) 1990-06-07
CA2002337C (en) 2000-07-04
JP3004663B2 (ja) 2000-01-31
EP0371683A1 (en) 1990-06-06

Similar Documents

Publication Publication Date Title
DE3886965D1 (de) Zubereitungen zur gesteuerten Wirkstofffreisetzung.
DK164388A (da) Praeparater til kontrolleret frigivelse
MX169808B (es) Formulaciones de gel que contienen factores de crecimiento
MX17752A (es) Formulaciones farmaceuticas y procedimiento para prepararlas
IT8921118A0 (it) Composizione per aerosol comprendente nitroglicerina come ingrediente attivo.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2052645T3 (es) Acidos poliinsaturados con accion vasocinetica y formulaciones farmaceuticas y cosmeticas que los contienen.
AU1454988A (en) Stable pharmaceutical w/o emulsion composition
DE10075031I2 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
IT7927524A0 (it) Proteine purificate e procedimento per la loro preparazione.
MX9200374A (es) Nuevos esteres esteroides, procedimiento para su preparacion y preparacion farmaceutica que los contiene.
PT83872A (de) Arzneimittel
MX9203394A (es) Benzazepinas substituidas, su preparacion y composiciones farmaceuticas que contienen las mismas.
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
NZ191630A (en) Medicated animal feeds containing liver meal
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
ES2014429B3 (es) Nuevas 4-triazol-4,3-a 1,4-benzodiazepinas, procedimiento para su preparacion, su aplicacion como medicamentos y preparaciones que las contienen.
AU1091483A (en) Anthralin or ester derivatives for skin diseases
AU6094690A (en) Long active injectable formulations containing triacetin
HUT42292A (en) Insecticidal compositions comprising fluorbenzyl esters as active substance and process for preparing the active substances
DK642588A (da) Indanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
ATE8460T1 (de) Pharmazeutische praeparate und deren herstellung.
ATE3282T1 (de) Alpha-difluormethyl-alpha-aminosaeuren und sie enthaltende pharmazeutische zusammensetzung.
NL185454C (nl) Esterderivaat van een anti-inflammatoir werkzaam carbonzuur, werkwijze voor het bereiden daarvan en farmaceutisch preparaat met anti-inflammatoire werking.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 371683

Country of ref document: ES